drug

lazertinib

1 story · latest Jul 15, 2026

Status: FDA approved Aug 2024 · NDA219008
Brand: Lazcluze

Relationships

Developed by Johnson & Johnson

Timeline

J&J raises 2026 sales and EPS guidance after strong Q2 results

Jul 15Quarterly updateJohnson & Johnson

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.